Ohio Recreational Marijuana Sales Could Launch In June Under Regulators’ Expedited Plan, Lawmaker Says
Pennsylvania Lawmakers File Marijuana Legalization Bill Ahead Of Committee Hearing This Week
Hawaii Senate Approves Marijuana Expungements Pilot Program
Washington D.C. Mayor Signs Bill Declaring 4/20 Tax Holiday On Medical Marijuana Purchases
Maine Lawmakers Send Governor Bill To Create Psychedelics Commission That Would Explore Regulated Access
Use Of Psilocybin For Mental Health Treatment ‘Not Associated’ With Risk Of Paranoia, American Medical Association Study Finds
More Than 90% Of Smokable Hemp Samples Analyzed By Researchers Contained Illegal Amounts Of THC, New Federal Study Finds
CBD’s Potential To Treat Pain, Cancer, Schizophrenia, COVID And Other Conditions Highlighted In New Scientific Review
Teen Marijuana Use Has Declined In Washington Since Legalization, New State Research Shows
A Citrusy-Smelling Terpene In Marijuana Can Reduce Anxiety And Paranoia Caused By THC, Federally Funded Study Finds
Former Minnesota Gov. Jesse Ventura Promotes New Cannabis Brand Ahead Of 4/20 That He’d ‘Offer To You’ On Governor’s Mansion Visit
Colorado Amendment Addresses Concerns On Banning Social Media Marijuana Posts, But Questions On Psychedelics And Other Drugs Remain
Former Minnesota Governor Jesse Ventura Launches His Own Cannabis Brand, Fulfilling A ‘Lifelong Dream’
Marijuana Rolling Paper Company Seeks Content Creator To ‘Get Paid To Smoke Weed’ For $70,420 Salary
Nevada’s First Marijuana Consumption Lounge Officially Opens, With Top Lawmaker Hitting A Joint At 4:20
Missouri Warns Marijuana License Applicants Of ‘Predatory Practices’ Around Social Equity Status
Missouri Marijuana Worker Union Dispute Could Have Major Implications For National Labor Law
New Mexico Retailers Set A New Marijuana Sales Record In March
Missouri Revokes Nine Marijuana Business Licenses Over Social Equity Ineligibility
Arizona Marijuana Sales Surpassed $1.4 Billion In 2023, With Bulk Of Transactions Coming From Adult-Use Buyers
Ohio Recreational Marijuana Sales Could Launch In June Under Regulators’ Expedited Plan, Lawmaker Says
Maine Lawmakers Send Governor Bill To Create Psychedelics Commission That Would Explore Regulated Access
As South Carolina Lawmakers Urge House Vote On Medical Marijuana Bill, New Poll Shows Strong Bipartisan Support
Florida Marijuana Initiative Will ‘Improve Quality Of Life’ By Providing Alcohol Alternative, Top Cannabis CEO Says, Pushing Back Against DeSantis
With Legalization Dead For The Session, Hawaii Lawmakers Advance Incremental Bills To Expand Decriminalization And Provide Expungements
Schumer cannabis legalization bill coming soon (Newsletter: April 10, 2024)
Feds seize state-licensed cannabis (Newsletter: April 9, 2024)
DOJ says legal cannabis boosts tourism (Newsletter: April 8, 2024)
Cannabis banking could help GOP keep House, lawmaker says (Newsletter: April 5, 2024)
FL legal cannabis campaign gets funding (Newsletter: April 4, 2024)
Published
on
By
Single-dose psilocybin use is “not associated with risk of paranoia,” while other adverse effects such as headaches are generally “tolerable and resolved within 48 hours”—according to a new scientific review published by the American Medical Association (AMA).
With increased public interest in the therapeutic potential of psychedelics, researchers at the University of Georgia, Larkin University and Palm Beach Atlantic University set out to better understand possible negative effects of receiving psilocybin treatment.
The study, published in JAMA Psychiatry on Wednesday, involved a meta-analysis of double-blind clinical trials where psilocybin was used to treat anxiety and depression from 1966 to last year.
While psychedelics are sometimes portrayed in media as causing intense paranoia, particularly in a recreational setting, the study authors said psilocybin “was not associated with risk of paranoia and transient thought disorder.”
The researchers identified five other reported adverse effects among certain patients in the clinical trials: headache, nausea, anxiety, dizziness and elevated blood pressure. But they said the acute adverse effect profile of therapeutic single-dose psilocybin appeared to be “tolerable and resolved within 48 hours.”
“However, future studies need to more actively evaluate the appropriate management of adverse effects,” the study says.
While serious adverse effects like paranoia and prolonged visual perceptual effects were “infrequent,” the team stressed that those rare cases “warrant attention” and should be “monitored over the long term.”
“The effectiveness of medications and alternative treatments in managing these symptoms requires further investigation,” the study says. “Additionally, the role of licensed therapists in managing adverse effects presents an avenue for future research.”
Meanwhile, AMA published a separate study last month that similarly contradicted commonly held beliefs about the potential risks of psychedelics use, finding the substances “may be associated with lower rates of psychotic symptoms among adolescents.”
Also, result of a clinical trial published by AMA in December “suggest efficacy and safety” of psilocybin-assisted psychotherapy for treatment of bipolar II disorder, a mental health condition often associated with debilitating and difficult-to-treat depressive episodes.
The association also published research last August that found people with major depression experienced “clinically significant sustained reduction” in their symptoms after just one dose of psilocybin.
Another recent study suggests that the use of full-spectrum psychedelic mushroom extract has a more powerful effect than chemically synthesized psilocybin alone, which could have implications for psychedelic-assisted therapy. The findings imply that the experience of entheogenic mushrooms may involve a so-called “entourage effect” similar to what’s observed with cannabis and its many components.
More Than 90% Of Smokable Hemp Samples Analyzed By Researchers Contained Illegal Amounts Of THC, New Federal Study Finds
Photo courtesy of Dick Culbert.
More Than 90% Of Smokable Hemp Samples Analyzed By Researchers Contained Illegal Amounts Of THC, New Federal Study Finds
Kyle Jaeger is Marijuana Moment’s Sacramento-based managing editor. His work has also appeared in High Times, VICE and attn.
All the cannabis news you need, all in one place. Copyright © 2017-2024 Marijuana Moment LLC ® and Tom Angell
Use Of Psilocybin For Mental Health Treatment 'Not Associated' With Risk Of Paranoia, American Medical Association … – Marijuana Moment
